⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING EJNMMI Research Pub Date : 2025-01-17 DOI:10.1186/s13550-025-01198-7

Yilin Li, Rongxi Wang, Jingci Chen, Zhaohui Zhu, Yu Wang, Wenbin Ma

{"title":"68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.","authors":"Yilin Li, Rongxi Wang, Jingci Chen, Zhaohui Zhu, Yu Wang, Wenbin Ma","doi":"10.1186/s13550-025-01198-7","DOIUrl":null,"url":null,"abstract":"Background: Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations.Results: Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited 68Ga-NOTA-RM26 uptake. SUVmax was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUVmax had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUVmax. P53 mutations caused significant differences in SUVmax (P = 0.03).Conclusions: This study is the first application of 68Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. 68Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations.Trial registration: ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"6"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11748694/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01198-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of ⁶⁸Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations.

Results: Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited ⁶⁸Ga-NOTA-RM26 uptake. SUV_max was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUV_max had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUV_max. P53 mutations caused significant differences in SUV_max (P = 0.03).

Conclusions: This study is the first application of ⁶⁸Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. ⁶⁸Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations.

Trial registration: ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

68Ga-NOTA-RM26 PET/CT在胶质瘤评估中的应用：一项前瞻性研究。

背景：神经胶质瘤是中枢神经系统最常见的原发性恶性肿瘤。目前迫切需要一种新的、方便的、靶向的、特异的胶质瘤显像剂。本研究旨在首先评价68Ga-NOTA-RM26 PET/CT成像在胶质瘤中的可行性，分析其影像学特征与胶质瘤分级、分型及分子改变的关系。结果：22例患者经手术或活检证实为胶质瘤。所有患者均出现68Ga-NOTA-RM26摄取。选择SUVmax作为成像标记物进行分析。对于所有胶质瘤患者，不同级别之间存在显著差异（P = 0.047）。对于原发性胶质瘤，SUVmax对肿瘤的分类（P = 0.045）和分级（P = 0.03）均有良好的鉴别能力。两者呈正相关（P > 0.05）。P53突变导致SUVmax差异有统计学意义（P = 0.03）。结论：本研究是68Ga-NOTA-RM26在胶质瘤患者中的首次应用，证实了其在胶质瘤患者中的安全性和有效性。68Ga-NOTA-RM26 PET/CT在肿瘤分级、分类和分子改变方面具有潜在价值。试验注册：ClinicalTrials.gov: NCT06412952。2024年4月26日注册，https://clinicaltrials.gov/study/NCT06412952。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.